市场调查报告书
商品编码
1433323
2023-2030 年全球心电图 (ECG) 遥测设备市场Global Electrocardiography (ECG) Telemetry Devices Market 2023-2030 |
预计在预测期内(2023-2030 年),全球心电图 (ECG) 遥测设备市场将以 5.6% 的CAGR成长。全球对技术进步的需求不断增长。心电图遥测设备与物联网和行动运算技术的整合扩大了其范围和有效性,允许远端监控和即时资料传输。据 MDPI 称,2020 年 2 月,世界卫生组织 (WHO) 报告称,心血管疾病 (CVD) 是全球主要死亡原因,每年导致 1,790 万人死亡。在美国,CVD 是最常见的死亡原因,2016 年导致超过 84 万人死亡。欧洲健康网络报告称,CVD 每年导致欧洲 390 万人死亡,欧盟 (EU) 180 万人死亡。 ,分别占这些地区所有死亡人数的45% 和37%。
此外,连续心率监测和即时心跳检测在医疗保健中至关重要,因为它们可以帮助诊断、治疗和预防心血管疾病 (CVD)。心电图讯号提供了一种全面的疾病评估方法,有助于疾病控制和预防。感测器技术的进步、通讯基础设施的进步、资料处理、建模和分析演算法可以解决损伤风险,从而进入智慧、主动医疗保健的新时代。心电图监测系统可用于医院、住宅、门诊流动环境和远端环境,包括使用物联网和行动电脑技术。
Global Electrocardiography (ECG) Telemetry Devices Market Size, Share & Trends Analysis Report by Technology (Single Stage and Double Stage), by Absorber Type (Lithium Bromide and Ammonia), by Power Source (Direct Fired, Indirect Fired, and Water Driven), and by Application (Chemicals, Food & Beverages, Power, Paper & Pulp, Power & Energy and Others), Forecast Period (2023-2030)
The global electrocardiography (ECG) telemetry devices market is anticipated to grow at a CAGR of 5.6% during the forecast period (2023-2030). The growing demand for technological advancements across the globe. The integration of ECG telemetry devices with IoT and mobile computing technology expands their reach and effectiveness, allowing for remote monitoring and data move in instantaneously. According to the MDPI, in February 2020, the World Health Organization (WHO) reported that cardiovascular diseases (CVDs) are the leading cause of death globally, accounting for 17.9 million deaths annually. In the US, CVDs are the most common cause of death, leading to more than 840,000 deaths in 2016. The European Health Network reported that CVDs are responsible for 3.9 million deaths in Europe and 1.8 million deaths in the European Union (EU) each year, which accounts for 45% and 37% of all deaths in those regions respectively.
Furthermore, continuous heart rate monitoring and immediate heartbeat detection are essential in healthcare since they can aid in the diagnosis, treatment, and prevention of cardiovascular diseases (CVDs). ECG signals provide a comprehensive approach to disease assessment, assisting in disease control and prevention. Sensor technology advancements, communication infrastructure advancements, data processing, modeling, and analytics algorithms can address impairment risks, resulting in a new era of smart, proactive healthcare. ECG monitoring systems are utilized in hospitals, residences, outpatient ambulatory settings, and distant contexts, including use of IoT and mobile computer technology.
The global electrocardiography (ECG) telemetry devices market is segmented on the product, application, and end-user. Based on the product, the market is sub-segmented into event monitoring
mobile ECG telemetry devices, implantable loop recorders, and others. Based on the application, the market is sub-segmented into arrhythmias, myocardial ischemia and infarction, pacemaker monitoring, and others. Furthermore, on the basis of end-user, the market is sub-segmented into hospitals and healthcare facilities, clinical research organizations (CROs), home healthcare providers, and others. The hospitals and healthcare facilities subcategory is expected to capture a significant portion of the market share within the end user segment. This is attributed to the increased use of ECG devices in cardiac settings across hospitals, as an electrocardiogram is the most commonly used diagnostic tool in the cardiac department.
Among the product, the implantable loop recorders sub-segment is expected to hold a considerable share of the global electrocardiography (ECG) telemetry devices market. The segmental growth is attributed to the stroke-related AF detection. The growing identification of atrial fibrillation (AF) as a significant risk factor in stroke patients is encouraging the use of ECG telemetry devices for monitoring and early detection. According to National Institute of Health (gov.), in July 2023, 20% of patients who have had an ischemic stroke or transient ischemic attack have a history of atrial fibrillation, and up to 23% of those with cryptogenic or non-cardioembolic stroke have unknown atrial fibrillation which can be detected using various monitoring strategies. To address gaps in monitoring time, randomized studies have been conducted, focusing on patients with cryptogenic stroke. Non-invasive monitoring tools such as implantable loop recorders (ILRs), external loop recorders (ELRs) and mobile cardiac outpatient telemetry (MCOT) are commonly used to monitor ECG in ambulatory settings. The aim of this review is to provide an overview of current evidence, techniques, and gaps in knowledge to advise which patients would benefit most from these monitoring tools.
The global electrocardiography (ECG) telemetry devices market is further segmented based on geography including North America (the US, and Canada), Europe (UK, Italy, Spain, Germany, France, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, and Rest of Asia), and the Rest of the World (the Middle East & Africa, and Latin America). Among these, Europe is anticipated to hold a prominent share of the market across the globe, owing to the growing public awareness of the significance of early diagnosis for better and more effective targeted treatment is projected to propel the ECG equipment business forward.
Among all regions, the North America regions is anticipated to grow at a considerable CAGR over the forecast period. Regional growth is attributed to the rising preventive healthcare awareness and focus across the region. Individuals are becoming more attentive of monitoring their health as the focus shifts toward preventive healthcare. ECG telemetry devices, particularly that designed for arrhythmia detection and atrial fibrillation, are in accordance with this trend owing to the enable early identification and intervention. According to the National Institute of Health (gov.), in July 2023, the manufacturers' intended use information was unavailable for 3% (2/58) of the devices. Of the 58 devices, 36% (21/58) do not state any intended use with regards to rhythm disorders. 53% (31/58) of the devices are intended to be used when there is suspicion of arrhythmias, and 10% (6/58) are intended to be used specifically for the detection of atrial fibrillation.
The major companies serving the electrocardiography (ECG) telemetry devices market include BIOTRONIK SE & Co KG, GE HealthCare Technologies Inc., Hill-Rom Holdings Inc., Philips International B.V., SCHILLER AG, and others. The market players are considerably contributing to the market growth by the adoption of various strategies including mergers and acquisitions, partnerships, collaborations, funding, and new product launches, to stay competitive in the market. For instance, in November 2021, Royal Philips acquired Cardiologs, to expand its cardiac diagnostics and monitoring portfolio including cardiac monitoring and diagnostics offering with innovative software technology, electrocardiogram (ECG) analysis and reporting services.